A Haynes and Boone, LLP deal team represented Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) in a $25 million public offering of its common stock.
Actinium is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates. It said in a statement that it intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, among other objectives.
New York Partner Rick Werner, co-chair of Haynes and Boone’s Capital Markets and Securities Practice Group, and Jayun Koo, a Partner in the New York Capital Markets and Securities Practice Group, led the team representing Actinium. They were assisted by Haynes and Boone lawyers: Greg Kramer, So Yung Kang, Eloise Rotenberg, Mike Haden, Jeff Wolfson, Evert Tu, Suzie Trigg, Phil Kim and Kayla Cristales.
Haynes and Boone’s Capital Markets and Securities Practice Group delivers strategic solutions and provides comprehensive advice on a full range of securities transactions and reporting matters. The group has helped companies raise capital and comply with evolving securities laws and practices for more than four decades, and it serves as securities counsel to more than 30 public companies ranging in size from small cap companies to large cap multi-national business entities.
Haynes and Boone is an international corporate law firm with offices in Texas, New York, California, Charlotte, Chicago, Denver, Washington, D.C., London, Mexico City and Shanghai, providing a full spectrum of legal services across a wide array of industries. With more than 575 lawyers, Haynes and Boone is ranked among the largest U.S.-based firms by The National Law Journal, The American Lawyer and The Lawyer. It also was recognized across the board for excellence in the BTI Consulting Group’s 2020 “A-Team” report, which identifies the law firms that in-house counsel single out for providing superior client service.